| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 106 | 2024 | 989 | 16.570 |
Why?
|
| Receptors, Complement 3d | 78 | 2023 | 129 | 10.790 |
Why?
|
| Complement Activation | 79 | 2023 | 350 | 8.620 |
Why?
|
| Complement Pathway, Alternative | 45 | 2022 | 117 | 7.870 |
Why?
|
| Arthritis, Experimental | 30 | 2020 | 133 | 7.630 |
Why?
|
| Complement System Proteins | 45 | 2023 | 294 | 7.150 |
Why?
|
| Autoantibodies | 74 | 2023 | 1335 | 6.270 |
Why?
|
| Receptors, Complement | 64 | 2022 | 115 | 5.640 |
Why?
|
| Rheumatoid Factor | 39 | 2024 | 156 | 5.620 |
Why?
|
| Complement C3 | 63 | 2023 | 192 | 4.810 |
Why?
|
| Complement C3d | 23 | 2023 | 60 | 4.490 |
Why?
|
| Peptides, Cyclic | 33 | 2023 | 260 | 3.980 |
Why?
|
| Complement Factor B | 26 | 2022 | 102 | 3.910 |
Why?
|
| Complement Factor H | 21 | 2022 | 61 | 3.880 |
Why?
|
| Receptors, Complement 3b | 56 | 2023 | 82 | 3.820 |
Why?
|
| Lupus Erythematosus, Systemic | 18 | 2022 | 227 | 3.370 |
Why?
|
| Autoimmunity | 28 | 2023 | 831 | 3.360 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 18 | 2023 | 89 | 3.300 |
Why?
|
| Immunoglobulin M | 26 | 2023 | 253 | 2.940 |
Why?
|
| Autoimmune Diseases | 18 | 2023 | 398 | 2.840 |
Why?
|
| B-Lymphocytes | 42 | 2023 | 770 | 2.780 |
Why?
|
| Complement Pathway, Mannose-Binding Lectin | 7 | 2020 | 26 | 2.730 |
Why?
|
| Mice | 171 | 2023 | 15520 | 2.470 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 6 | 2020 | 22 | 2.340 |
Why?
|
| Reperfusion Injury | 18 | 2021 | 276 | 2.270 |
Why?
|
| Rheumatology | 6 | 2023 | 87 | 2.190 |
Why?
|
| Complement Inactivating Agents | 7 | 2021 | 43 | 2.180 |
Why?
|
| Animals | 200 | 2023 | 33381 | 2.090 |
Why?
|
| Antibodies, Monoclonal | 38 | 2023 | 1284 | 2.080 |
Why?
|
| Antigen-Antibody Complex | 12 | 2019 | 90 | 2.060 |
Why?
|
| Recombinant Fusion Proteins | 21 | 2023 | 653 | 1.990 |
Why?
|
| Complement C3a | 6 | 2019 | 33 | 1.980 |
Why?
|
| Complement C3b | 14 | 2023 | 30 | 1.980 |
Why?
|
| Mice, Knockout | 60 | 2021 | 2680 | 1.950 |
Why?
|
| Choroidal Neovascularization | 5 | 2019 | 44 | 1.910 |
Why?
|
| Complement Inactivator Proteins | 21 | 2010 | 39 | 1.900 |
Why?
|
| Epitopes | 24 | 2023 | 443 | 1.810 |
Why?
|
| Kidney Glomerulus | 18 | 2021 | 133 | 1.760 |
Why?
|
| Complement Factor D | 9 | 2020 | 28 | 1.750 |
Why?
|
| Synovial Membrane | 11 | 2024 | 71 | 1.740 |
Why?
|
| Immunoglobulin G | 31 | 2023 | 788 | 1.710 |
Why?
|
| Complement C3b Inactivator Proteins | 4 | 2017 | 9 | 1.710 |
Why?
|
| Humans | 272 | 2024 | 118972 | 1.680 |
Why?
|
| Inflammation | 22 | 2023 | 2566 | 1.650 |
Why?
|
| Mice, Inbred C57BL | 73 | 2022 | 4908 | 1.650 |
Why?
|
| Immunoglobulin A | 10 | 2023 | 174 | 1.640 |
Why?
|
| Antirheumatic Agents | 9 | 2024 | 254 | 1.570 |
Why?
|
| Hydrolases | 4 | 2021 | 51 | 1.380 |
Why?
|
| Pre-Eclampsia | 4 | 2015 | 183 | 1.370 |
Why?
|
| Complement Membrane Attack Complex | 7 | 2019 | 35 | 1.240 |
Why?
|
| Immune System Diseases | 3 | 2015 | 35 | 1.190 |
Why?
|
| Joints | 8 | 2020 | 85 | 1.190 |
Why?
|
| Citrulline | 7 | 2017 | 41 | 1.170 |
Why?
|
| Biomarkers | 34 | 2022 | 3588 | 1.160 |
Why?
|
| Retinal Pigment Epithelium | 4 | 2017 | 60 | 1.150 |
Why?
|
| Disease Models, Animal | 36 | 2022 | 3730 | 1.150 |
Why?
|
| Kidney Diseases | 7 | 2023 | 439 | 1.090 |
Why?
|
| Collagen Type II | 7 | 2013 | 48 | 1.040 |
Why?
|
| Antigens, CD | 13 | 2010 | 460 | 1.040 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2023 | 2275 | 1.020 |
Why?
|
| Antibody Formation | 12 | 2023 | 276 | 1.020 |
Why?
|
| Immunity, Innate | 11 | 2017 | 745 | 1.000 |
Why?
|
| Mucous Membrane | 3 | 2023 | 113 | 0.970 |
Why?
|
| Herpesvirus 4, Human | 13 | 2022 | 126 | 0.940 |
Why?
|
| Female | 117 | 2024 | 61564 | 0.930 |
Why?
|
| Single-Chain Antibodies | 2 | 2020 | 14 | 0.900 |
Why?
|
| Meniscus | 1 | 2023 | 22 | 0.890 |
Why?
|
| Protein Binding | 22 | 2019 | 1975 | 0.880 |
Why?
|
| Receptors, Antigen, B-Cell | 8 | 2012 | 101 | 0.880 |
Why?
|
| Male | 114 | 2024 | 57801 | 0.870 |
Why?
|
| Cytokines | 20 | 2023 | 1900 | 0.820 |
Why?
|
| Rheumatic Diseases | 3 | 2020 | 49 | 0.800 |
Why?
|
| Disease Progression | 14 | 2021 | 2490 | 0.800 |
Why?
|
| Complement C3-C5 Convertases | 7 | 2019 | 19 | 0.790 |
Why?
|
| Macular Degeneration | 5 | 2022 | 151 | 0.790 |
Why?
|
| Arthralgia | 2 | 2021 | 51 | 0.790 |
Why?
|
| Prodromal Symptoms | 1 | 2020 | 13 | 0.780 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 73 | 0.780 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 14 | 2020 | 827 | 0.780 |
Why?
|
| Lasers | 2 | 2012 | 124 | 0.770 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2023 | 147 | 0.770 |
Why?
|
| Synoviocytes | 1 | 2020 | 10 | 0.770 |
Why?
|
| Kidney | 13 | 2023 | 1353 | 0.770 |
Why?
|
| Antibodies, Antiphospholipid | 4 | 2005 | 22 | 0.750 |
Why?
|
| Interferon-alpha | 4 | 2010 | 191 | 0.740 |
Why?
|
| Osteoarthritis, Knee | 1 | 2023 | 223 | 0.730 |
Why?
|
| Antibodies | 9 | 2017 | 392 | 0.720 |
Why?
|
| Glomerulonephritis | 8 | 2023 | 60 | 0.720 |
Why?
|
| Fetal Death | 3 | 2005 | 52 | 0.720 |
Why?
|
| Chemokines | 3 | 2012 | 230 | 0.720 |
Why?
|
| Erythrocytes | 15 | 2016 | 641 | 0.720 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 187 | 0.710 |
Why?
|
| Middle Aged | 63 | 2024 | 27617 | 0.710 |
Why?
|
| Ligands | 16 | 2019 | 567 | 0.700 |
Why?
|
| Organ Specificity | 10 | 2019 | 278 | 0.700 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2023 | 247 | 0.690 |
Why?
|
| Membrane Glycoproteins | 12 | 2020 | 446 | 0.690 |
Why?
|
| Methotrexate | 4 | 2024 | 227 | 0.690 |
Why?
|
| Cell Line | 30 | 2017 | 2707 | 0.690 |
Why?
|
| Nuclear Family | 1 | 2019 | 54 | 0.690 |
Why?
|
| Collagen | 7 | 2017 | 433 | 0.680 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 32 | 0.680 |
Why?
|
| Asymptomatic Diseases | 2 | 2021 | 81 | 0.680 |
Why?
|
| Geographic Atrophy | 1 | 2019 | 49 | 0.670 |
Why?
|
| Lectins | 3 | 2019 | 50 | 0.670 |
Why?
|
| Receptor, Anaphylatoxin C5a | 6 | 2018 | 30 | 0.670 |
Why?
|
| RNA Interference | 2 | 2020 | 460 | 0.660 |
Why?
|
| Hemolysis | 4 | 2017 | 174 | 0.630 |
Why?
|
| Disease Susceptibility | 7 | 2020 | 331 | 0.620 |
Why?
|
| Binding Sites | 18 | 2021 | 1224 | 0.620 |
Why?
|
| Kidney Tubules | 6 | 2011 | 128 | 0.610 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 827 | 0.610 |
Why?
|
| Mice, Inbred BALB C | 26 | 2023 | 1206 | 0.600 |
Why?
|
| Risk Factors | 24 | 2022 | 9000 | 0.590 |
Why?
|
| Synovitis | 2 | 2023 | 24 | 0.580 |
Why?
|
| Mice, Inbred DBA | 7 | 2020 | 174 | 0.580 |
Why?
|
| Peptide Fragments | 9 | 2017 | 702 | 0.580 |
Why?
|
| Complement Pathway, Classical | 5 | 2021 | 19 | 0.580 |
Why?
|
| Adult | 52 | 2022 | 31512 | 0.580 |
Why?
|
| Case-Control Studies | 17 | 2021 | 3171 | 0.570 |
Why?
|
| Membrane Proteins | 9 | 2010 | 1055 | 0.570 |
Why?
|
| Plasma Cells | 1 | 2016 | 59 | 0.570 |
Why?
|
| Antigens | 6 | 2015 | 320 | 0.550 |
Why?
|
| Transcription, Genetic | 3 | 2020 | 1323 | 0.550 |
Why?
|
| Sputum | 4 | 2021 | 290 | 0.550 |
Why?
|
| Gene Expression | 10 | 2022 | 1489 | 0.550 |
Why?
|
| Benzimidazoles | 1 | 2017 | 140 | 0.550 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2018 | 408 | 0.550 |
Why?
|
| Receptors, IgE | 4 | 2010 | 40 | 0.540 |
Why?
|
| Models, Immunological | 3 | 2011 | 94 | 0.540 |
Why?
|
| Hemoglobinuria, Paroxysmal | 3 | 2012 | 5 | 0.540 |
Why?
|
| Fibrinogen | 3 | 2022 | 161 | 0.530 |
Why?
|
| Smoking | 7 | 2020 | 1487 | 0.530 |
Why?
|
| Mice, Transgenic | 22 | 2013 | 2025 | 0.520 |
Why?
|
| Inflammation Mediators | 5 | 2020 | 502 | 0.520 |
Why?
|
| Autoantigens | 9 | 2023 | 397 | 0.520 |
Why?
|
| Lymphoid Tissue | 4 | 2022 | 65 | 0.510 |
Why?
|
| Antigens, CD19 | 6 | 2015 | 96 | 0.500 |
Why?
|
| RNA, Messenger | 18 | 2022 | 2657 | 0.500 |
Why?
|
| Cloning, Molecular | 12 | 2017 | 546 | 0.500 |
Why?
|
| Complement C6 | 3 | 2018 | 9 | 0.490 |
Why?
|
| Recombinant Proteins | 13 | 2021 | 1308 | 0.480 |
Why?
|
| Lymphocyte Activation | 17 | 2021 | 1067 | 0.480 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 82 | 0.470 |
Why?
|
| Adenoviridae | 1 | 2014 | 191 | 0.470 |
Why?
|
| Gene Expression Regulation | 14 | 2016 | 2445 | 0.470 |
Why?
|
| Receptors, Cell Surface | 8 | 2010 | 367 | 0.460 |
Why?
|
| Cells, Cultured | 17 | 2020 | 4077 | 0.450 |
Why?
|
| DNA | 10 | 2012 | 1388 | 0.450 |
Why?
|
| Polymorphism, Genetic | 8 | 2008 | 642 | 0.450 |
Why?
|
| Epithelial Cells | 7 | 2011 | 963 | 0.450 |
Why?
|
| Prospective Studies | 18 | 2022 | 6471 | 0.450 |
Why?
|
| Spleen | 8 | 2013 | 510 | 0.450 |
Why?
|
| Arthritis, Juvenile | 2 | 2021 | 42 | 0.440 |
Why?
|
| Complement C1q | 6 | 2013 | 38 | 0.440 |
Why?
|
| Models, Molecular | 14 | 2021 | 1435 | 0.440 |
Why?
|
| Aged | 34 | 2021 | 19657 | 0.440 |
Why?
|
| CD55 Antigens | 12 | 2019 | 26 | 0.440 |
Why?
|
| Signal Transduction | 18 | 2020 | 4709 | 0.440 |
Why?
|
| Molecular Sequence Data | 25 | 2015 | 2871 | 0.430 |
Why?
|
| Molecular Targeted Therapy | 4 | 2017 | 356 | 0.430 |
Why?
|
| Blotting, Western | 15 | 2016 | 1194 | 0.420 |
Why?
|
| Pregnancy | 15 | 2015 | 5690 | 0.420 |
Why?
|
| Nephritis | 1 | 2012 | 30 | 0.420 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 681 | 0.420 |
Why?
|
| Flow Cytometry | 13 | 2019 | 1085 | 0.410 |
Why?
|
| Transfection | 7 | 2020 | 888 | 0.410 |
Why?
|
| Sheep | 11 | 2015 | 764 | 0.410 |
Why?
|
| Complement C5 | 5 | 2020 | 75 | 0.410 |
Why?
|
| Mass Screening | 3 | 2020 | 1052 | 0.410 |
Why?
|
| T-Lymphocytes | 13 | 2023 | 1774 | 0.400 |
Why?
|
| Amidines | 1 | 2011 | 16 | 0.400 |
Why?
|
| Ornithine | 1 | 2011 | 22 | 0.400 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2017 | 125 | 0.390 |
Why?
|
| Protein-Arginine Deiminases | 4 | 2021 | 17 | 0.390 |
Why?
|
| gamma-Glutamyltransferase | 3 | 1999 | 43 | 0.390 |
Why?
|
| Extracellular Traps | 3 | 2021 | 40 | 0.390 |
Why?
|
| Family | 6 | 2021 | 585 | 0.390 |
Why?
|
| Pregnancy Complications | 4 | 2011 | 448 | 0.390 |
Why?
|
| Apoptosis | 5 | 2020 | 2484 | 0.390 |
Why?
|
| Obesity | 3 | 2020 | 2746 | 0.390 |
Why?
|
| Complement Activating Enzymes | 2 | 2010 | 4 | 0.390 |
Why?
|
| RNA, Small Interfering | 3 | 2020 | 564 | 0.390 |
Why?
|
| Annexin A4 | 2 | 2015 | 5 | 0.390 |
Why?
|
| Gene Silencing | 2 | 2001 | 177 | 0.380 |
Why?
|
| Mice, Inbred MRL lpr | 10 | 2019 | 39 | 0.380 |
Why?
|
| Drug Discovery | 1 | 2011 | 124 | 0.380 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 67 | 0.380 |
Why?
|
| Logistic Models | 8 | 2015 | 1901 | 0.370 |
Why?
|
| Extracellular Space | 2 | 2008 | 127 | 0.370 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2012 | 181 | 0.370 |
Why?
|
| Thrombotic Microangiopathies | 3 | 2017 | 18 | 0.370 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 219 | 0.370 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2021 | 39 | 0.370 |
Why?
|
| Health Fairs | 1 | 2009 | 9 | 0.360 |
Why?
|
| B-Lymphocyte Subsets | 4 | 2010 | 66 | 0.360 |
Why?
|
| Amino Acid Sequence | 20 | 2021 | 2071 | 0.360 |
Why?
|
| Acute Kidney Injury | 6 | 2018 | 709 | 0.360 |
Why?
|
| Premature Birth | 2 | 2015 | 284 | 0.360 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2013 | 984 | 0.360 |
Why?
|
| Family Health | 2 | 2013 | 201 | 0.360 |
Why?
|
| Immunity, Humoral | 4 | 2015 | 117 | 0.360 |
Why?
|
| Antibodies, Bacterial | 3 | 2020 | 126 | 0.360 |
Why?
|
| Predictive Value of Tests | 8 | 2013 | 1868 | 0.350 |
Why?
|
| Immunologic Factors | 3 | 2022 | 225 | 0.350 |
Why?
|
| Surface Plasmon Resonance | 5 | 2013 | 85 | 0.350 |
Why?
|
| Neutrophils | 7 | 2015 | 1233 | 0.350 |
Why?
|
| Calcium Signaling | 2 | 2008 | 219 | 0.350 |
Why?
|
| Diabetic Retinopathy | 2 | 2022 | 160 | 0.350 |
Why?
|
| Intestines | 4 | 2021 | 332 | 0.350 |
Why?
|
| Repressor Proteins | 4 | 2019 | 377 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 2062 | 0.340 |
Why?
|
| Base Sequence | 20 | 2015 | 2159 | 0.340 |
Why?
|
| Cell Differentiation | 6 | 2007 | 1753 | 0.340 |
Why?
|
| Abortion, Spontaneous | 3 | 2006 | 94 | 0.340 |
Why?
|
| Immunohistochemistry | 12 | 2016 | 1691 | 0.330 |
Why?
|
| Self Tolerance | 3 | 2019 | 28 | 0.330 |
Why?
|
| Immunoglobulins | 10 | 2020 | 154 | 0.330 |
Why?
|
| Mutagenesis, Site-Directed | 7 | 2016 | 363 | 0.330 |
Why?
|
| Severity of Illness Index | 9 | 2022 | 2674 | 0.330 |
Why?
|
| Early Diagnosis | 4 | 2018 | 230 | 0.330 |
Why?
|
| Retina | 1 | 2011 | 278 | 0.320 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 3 | 2016 | 46 | 0.320 |
Why?
|
| Leukocytes | 5 | 2019 | 290 | 0.320 |
Why?
|
| Rats | 14 | 2023 | 5392 | 0.320 |
Why?
|
| Antibody Specificity | 5 | 2021 | 184 | 0.320 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 509 | 0.320 |
Why?
|
| Cell Membrane | 6 | 2022 | 710 | 0.320 |
Why?
|
| Alleles | 7 | 2019 | 832 | 0.310 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 8 | 1992 | 34 | 0.300 |
Why?
|
| Intestinal Mucosa | 3 | 2009 | 531 | 0.300 |
Why?
|
| Up-Regulation | 6 | 2013 | 872 | 0.300 |
Why?
|
| Dextrans | 3 | 2016 | 74 | 0.300 |
Why?
|
| Nanoparticles | 3 | 2023 | 325 | 0.300 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 64 | 0.300 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2014 | 16 | 0.290 |
Why?
|
| Clonal Anergy | 5 | 2012 | 54 | 0.290 |
Why?
|
| Complement C4 | 7 | 2009 | 26 | 0.290 |
Why?
|
| Promoter Regions, Genetic | 5 | 2018 | 1158 | 0.290 |
Why?
|
| Immunization, Passive | 1 | 2006 | 81 | 0.280 |
Why?
|
| Viral Matrix Proteins | 4 | 2008 | 24 | 0.280 |
Why?
|
| Monocytes | 5 | 2020 | 513 | 0.280 |
Why?
|
| Tissue Distribution | 4 | 2022 | 334 | 0.280 |
Why?
|
| In Vitro Techniques | 10 | 2010 | 1094 | 0.280 |
Why?
|
| Time Factors | 10 | 2019 | 6412 | 0.270 |
Why?
|
| Dendritic Cells | 3 | 2022 | 442 | 0.270 |
Why?
|
| Blood Platelets | 4 | 2015 | 369 | 0.270 |
Why?
|
| Epitope Mapping | 2 | 2005 | 49 | 0.270 |
Why?
|
| Lupus Nephritis | 5 | 2010 | 55 | 0.270 |
Why?
|
| Calcium | 5 | 2012 | 1169 | 0.270 |
Why?
|
| Epithelium | 2 | 2006 | 305 | 0.270 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2021 | 464 | 0.270 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2003 | 29 | 0.260 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2005 | 25 | 0.260 |
Why?
|
| Antigens, Surface | 9 | 2006 | 156 | 0.260 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2006 | 131 | 0.260 |
Why?
|
| Head Injuries, Closed | 3 | 2016 | 55 | 0.260 |
Why?
|
| Protein Conformation | 10 | 2021 | 848 | 0.260 |
Why?
|
| Risk | 3 | 2016 | 853 | 0.260 |
Why?
|
| Cartilage | 3 | 2017 | 183 | 0.260 |
Why?
|
| HLA-DR4 Antigen | 1 | 2005 | 75 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2012 | 527 | 0.250 |
Why?
|
| Caspases | 1 | 2006 | 269 | 0.250 |
Why?
|
| Multigene Family | 5 | 2009 | 200 | 0.250 |
Why?
|
| Magnetite Nanoparticles | 4 | 2019 | 28 | 0.250 |
Why?
|
| Cattle | 4 | 2015 | 978 | 0.250 |
Why?
|
| K562 Cells | 5 | 2015 | 73 | 0.240 |
Why?
|
| CD59 Antigens | 8 | 2011 | 21 | 0.240 |
Why?
|
| Complement C5a | 5 | 2018 | 60 | 0.240 |
Why?
|
| Fibroblasts | 3 | 2020 | 842 | 0.240 |
Why?
|
| Phenotype | 13 | 2023 | 3003 | 0.240 |
Why?
|
| Central Nervous System | 1 | 2006 | 245 | 0.240 |
Why?
|
| Epidermolysis Bullosa Acquisita | 2 | 2018 | 6 | 0.240 |
Why?
|
| Odds Ratio | 3 | 2019 | 996 | 0.240 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2014 | 17 | 0.240 |
Why?
|
| Protein Structure, Quaternary | 3 | 2010 | 116 | 0.240 |
Why?
|
| Communicable Diseases | 3 | 2007 | 132 | 0.230 |
Why?
|
| Binding, Competitive | 5 | 2006 | 205 | 0.230 |
Why?
|
| Vitreous Body | 2 | 2022 | 104 | 0.230 |
Why?
|
| Receptors, Virus | 5 | 2004 | 78 | 0.230 |
Why?
|
| Diagnostic Imaging | 2 | 2016 | 294 | 0.220 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2020 | 88 | 0.220 |
Why?
|
| Genes | 7 | 1995 | 231 | 0.220 |
Why?
|
| Protein Multimerization | 2 | 2021 | 161 | 0.220 |
Why?
|
| NF-kappa B | 1 | 2007 | 670 | 0.220 |
Why?
|
| Introns | 4 | 1998 | 234 | 0.220 |
Why?
|
| Periodontal Diseases | 1 | 2023 | 58 | 0.220 |
Why?
|
| Terminology as Topic | 2 | 2021 | 211 | 0.220 |
Why?
|
| Cartilage, Articular | 1 | 2006 | 306 | 0.210 |
Why?
|
| Complement Factor I | 3 | 2022 | 12 | 0.210 |
Why?
|
| Peptides | 4 | 2013 | 879 | 0.210 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 15 | 0.210 |
Why?
|
| Transgenes | 5 | 2011 | 174 | 0.210 |
Why?
|
| Citrullination | 2 | 2020 | 12 | 0.210 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2001 | 80 | 0.210 |
Why?
|
| Pedigree | 4 | 2020 | 485 | 0.200 |
Why?
|
| Electroretinography | 2 | 2012 | 41 | 0.200 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 33 | 0.200 |
Why?
|
| Trypsin | 2 | 2021 | 72 | 0.200 |
Why?
|
| Nephrosis, Lipoid | 1 | 2021 | 31 | 0.200 |
Why?
|
| C-Reactive Protein | 6 | 2018 | 360 | 0.200 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2012 | 180 | 0.200 |
Why?
|
| Drug Design | 2 | 2013 | 160 | 0.200 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 969 | 0.200 |
Why?
|
| Porphyromonas gingivalis | 2 | 2012 | 15 | 0.200 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 89 | 0.200 |
Why?
|
| Cohort Studies | 10 | 2022 | 5116 | 0.200 |
Why?
|
| Cardiolipins | 1 | 2021 | 73 | 0.190 |
Why?
|
| Retinal Drusen | 1 | 2021 | 25 | 0.190 |
Why?
|
| Protein Structure, Tertiary | 8 | 2012 | 823 | 0.190 |
Why?
|
| Neuroprotective Agents | 2 | 2016 | 111 | 0.190 |
Why?
|
| Transplants | 1 | 2021 | 36 | 0.190 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 2015 | 56 | 0.190 |
Why?
|
| Thymocytes | 1 | 2020 | 29 | 0.190 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2021 | 86 | 0.190 |
Why?
|
| Polysaccharides | 3 | 2010 | 78 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2016 | 982 | 0.190 |
Why?
|
| Periodontitis | 2 | 2012 | 42 | 0.190 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.190 |
Why?
|
| Lipopolysaccharides | 5 | 2020 | 870 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 59 | 0.190 |
Why?
|
| Chemokine CXCL16 | 1 | 2020 | 4 | 0.190 |
Why?
|
| Lung Diseases | 3 | 2013 | 718 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2020 | 410 | 0.190 |
Why?
|
| Proteolysis | 2 | 2021 | 146 | 0.190 |
Why?
|
| Solutions | 6 | 2012 | 156 | 0.190 |
Why?
|
| Mannose-Binding Lectin | 3 | 2016 | 21 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 5 | 2020 | 55 | 0.190 |
Why?
|
| Doxorubicin | 4 | 2023 | 302 | 0.180 |
Why?
|
| Women's Health | 4 | 2017 | 274 | 0.180 |
Why?
|
| Thrombin | 1 | 2021 | 143 | 0.180 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 95 | 0.180 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 167 | 0.180 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 40 | 0.180 |
Why?
|
| Bacteriophages | 1 | 2021 | 76 | 0.180 |
Why?
|
| Histones | 3 | 2021 | 552 | 0.180 |
Why?
|
| Adaptive Immunity | 2 | 2012 | 161 | 0.180 |
Why?
|
| Muramidase | 1 | 2020 | 72 | 0.180 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 43 | 0.180 |
Why?
|
| Opsonin Proteins | 2 | 2015 | 26 | 0.180 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 542 | 0.180 |
Why?
|
| Computational Biology | 2 | 2021 | 588 | 0.180 |
Why?
|
| Synovial Fluid | 3 | 2020 | 56 | 0.180 |
Why?
|
| Genotype | 6 | 2018 | 1882 | 0.180 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 3 | 2010 | 240 | 0.170 |
Why?
|
| Insulin-Secreting Cells | 1 | 2023 | 330 | 0.170 |
Why?
|
| Mouth Mucosa | 2 | 2023 | 82 | 0.170 |
Why?
|
| Fluorescein Angiography | 1 | 2019 | 103 | 0.170 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 1795 | 0.170 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2011 | 24 | 0.170 |
Why?
|
| Structure-Activity Relationship | 6 | 2021 | 522 | 0.170 |
Why?
|
| Lung | 7 | 2018 | 3664 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1597 | 0.170 |
Why?
|
| Bleomycin | 2 | 2018 | 228 | 0.170 |
Why?
|
| Postmenopause | 3 | 2017 | 305 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2020 | 320 | 0.170 |
Why?
|
| Cell Adhesion | 5 | 2003 | 443 | 0.170 |
Why?
|
| Endothelial Cells | 2 | 2021 | 732 | 0.160 |
Why?
|
| Lung Transplantation | 1 | 2021 | 263 | 0.160 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.160 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 1998 | 6 | 0.160 |
Why?
|
| Proteomics | 4 | 2018 | 876 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 4 | 2014 | 146 | 0.160 |
Why?
|
| Nuclear Proteins | 2 | 2001 | 597 | 0.160 |
Why?
|
| Virus Attachment | 2 | 2008 | 11 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 126 | 0.160 |
Why?
|
| Macrophage-1 Antigen | 3 | 2005 | 36 | 0.160 |
Why?
|
| Immunologic Memory | 2 | 1999 | 313 | 0.160 |
Why?
|
| Lung Injury | 1 | 2021 | 210 | 0.160 |
Why?
|
| Ultracentrifugation | 7 | 2012 | 49 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 2 | 2019 | 551 | 0.160 |
Why?
|
| Body Mass Index | 2 | 2019 | 2092 | 0.160 |
Why?
|
| Vascular Remodeling | 1 | 2020 | 152 | 0.160 |
Why?
|
| Cell Death | 3 | 2016 | 339 | 0.160 |
Why?
|
| Mice, Inbred NZB | 2 | 2003 | 17 | 0.160 |
Why?
|
| Gene Frequency | 2 | 2019 | 513 | 0.160 |
Why?
|
| Complement C4b-Binding Protein | 1 | 2017 | 3 | 0.160 |
Why?
|
| Phosphorylation | 6 | 2012 | 1633 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2015 | 219 | 0.160 |
Why?
|
| Tetanus Toxin | 1 | 2017 | 5 | 0.160 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 3 | 2008 | 14 | 0.160 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2011 | 95 | 0.160 |
Why?
|
| Immunoglobulin D | 2 | 2015 | 28 | 0.160 |
Why?
|
| Endothelium, Vascular | 4 | 2018 | 907 | 0.160 |
Why?
|
| B7-1 Antigen | 1 | 1998 | 69 | 0.160 |
Why?
|
| Collectins | 1 | 2017 | 12 | 0.160 |
Why?
|
| Oxidative Stress | 4 | 2013 | 1178 | 0.160 |
Why?
|
| Cell-Derived Microparticles | 1 | 2018 | 62 | 0.150 |
Why?
|
| Global Health | 1 | 2020 | 310 | 0.150 |
Why?
|
| Incidence | 6 | 2021 | 2424 | 0.150 |
Why?
|
| Pregnancy Outcome | 2 | 2011 | 349 | 0.150 |
Why?
|
| Genetic Variation | 4 | 2021 | 926 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 453 | 0.150 |
Why?
|
| Brain Injuries | 3 | 2007 | 484 | 0.150 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 128 | 0.150 |
Why?
|
| Environment | 1 | 2019 | 346 | 0.150 |
Why?
|
| Down-Regulation | 4 | 2015 | 627 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2017 | 89 | 0.150 |
Why?
|
| Genes, Immunoglobulin Light Chain | 1 | 2016 | 5 | 0.150 |
Why?
|
| Proteinuria | 4 | 2012 | 99 | 0.150 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.150 |
Why?
|
| Macrophages | 7 | 2015 | 1324 | 0.150 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 122 | 0.150 |
Why?
|
| Lymphocyte Depletion | 3 | 2013 | 119 | 0.150 |
Why?
|
| Sex Factors | 2 | 2020 | 1781 | 0.150 |
Why?
|
| Coronary Disease | 2 | 2017 | 356 | 0.140 |
Why?
|
| Adiponectin | 1 | 2018 | 226 | 0.140 |
Why?
|
| Solubility | 5 | 2006 | 235 | 0.140 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2016 | 58 | 0.140 |
Why?
|
| Crystallography, X-Ray | 6 | 2012 | 422 | 0.140 |
Why?
|
| Blotting, Northern | 7 | 1995 | 194 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2020 | 545 | 0.140 |
Why?
|
| Neurons | 5 | 2016 | 1345 | 0.140 |
Why?
|
| Immunoglobulin Isotypes | 3 | 2022 | 32 | 0.140 |
Why?
|
| Annexin A2 | 1 | 2016 | 10 | 0.140 |
Why?
|
| Mucin-5B | 1 | 2018 | 175 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2017 | 230 | 0.140 |
Why?
|
| Plasmids | 3 | 2012 | 355 | 0.140 |
Why?
|
| Liver | 3 | 2020 | 1816 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 942 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2020 | 3057 | 0.140 |
Why?
|
| Carrier Proteins | 3 | 2020 | 726 | 0.140 |
Why?
|
| Brain | 5 | 2016 | 2490 | 0.140 |
Why?
|
| Ferrosoferric Oxide | 2 | 2019 | 26 | 0.130 |
Why?
|
| Genes, RAG-1 | 2 | 2012 | 12 | 0.130 |
Why?
|
| Molecular Weight | 6 | 2006 | 343 | 0.130 |
Why?
|
| Immune Complex Diseases | 2 | 2008 | 9 | 0.130 |
Why?
|
| Blood Proteins | 2 | 2015 | 248 | 0.130 |
Why?
|
| Immune Tolerance | 2 | 2012 | 334 | 0.130 |
Why?
|
| Prognosis | 4 | 2020 | 3443 | 0.130 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2015 | 6 | 0.130 |
Why?
|
| Repetitive Sequences, Amino Acid | 3 | 2005 | 16 | 0.130 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 126 | 0.130 |
Why?
|
| Biological Evolution | 5 | 1995 | 443 | 0.130 |
Why?
|
| Phospholipids | 2 | 2015 | 208 | 0.130 |
Why?
|
| Myocardial Reperfusion | 1 | 2015 | 53 | 0.130 |
Why?
|
| Age Factors | 3 | 2019 | 2995 | 0.130 |
Why?
|
| Stroke | 2 | 2015 | 1047 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 652 | 0.130 |
Why?
|
| Membrane Cofactor Protein | 6 | 2010 | 12 | 0.130 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 4552 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1993 | 211 | 0.130 |
Why?
|
| Antibodies, Bispecific | 1 | 2015 | 33 | 0.130 |
Why?
|
| Consensus Sequence | 5 | 2003 | 70 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2006 | 65 | 0.130 |
Why?
|
| Ross River virus | 1 | 2014 | 23 | 0.120 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2015 | 105 | 0.120 |
Why?
|
| Young Adult | 8 | 2021 | 10793 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2021 | 9342 | 0.120 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 184 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 116 | 0.120 |
Why?
|
| Ischemia | 2 | 2011 | 374 | 0.120 |
Why?
|
| Species Specificity | 5 | 2009 | 565 | 0.120 |
Why?
|
| Bone and Bones | 1 | 2017 | 289 | 0.120 |
Why?
|
| Alphavirus Infections | 1 | 2014 | 42 | 0.120 |
Why?
|
| Amino Acid Substitution | 4 | 2010 | 276 | 0.120 |
Why?
|
| Renal Circulation | 2 | 2006 | 75 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2874 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2022 | 355 | 0.120 |
Why?
|
| Rabbits | 2 | 2011 | 780 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 1474 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 755 | 0.120 |
Why?
|
| Transcriptome | 1 | 2019 | 756 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2014 | 1012 | 0.120 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1993 | 68 | 0.110 |
Why?
|
| Rosette Formation | 4 | 1995 | 16 | 0.110 |
Why?
|
| Diet | 1 | 2020 | 1153 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2008 | 204 | 0.110 |
Why?
|
| Immunization | 3 | 2008 | 412 | 0.110 |
Why?
|
| Bacteroidaceae Infections | 1 | 2012 | 4 | 0.110 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 86 | 0.110 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 403 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2014 | 193 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 867 | 0.110 |
Why?
|
| Astrocytes | 4 | 2014 | 177 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2020 | 972 | 0.110 |
Why?
|
| Vitamin D | 2 | 2022 | 354 | 0.110 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 50 | 0.110 |
Why?
|
| Craniocerebral Trauma | 1 | 2014 | 146 | 0.110 |
Why?
|
| Cytoprotection | 1 | 2012 | 55 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2015 | 413 | 0.110 |
Why?
|
| Dose-Response Relationship, Immunologic | 3 | 2010 | 82 | 0.110 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2018 | 451 | 0.110 |
Why?
|
| Precipitin Tests | 5 | 1997 | 93 | 0.110 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2011 | 20 | 0.100 |
Why?
|
| Bronchial Diseases | 1 | 2011 | 34 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 589 | 0.100 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 2513 | 0.100 |
Why?
|
| Macaca fascicularis | 1 | 2011 | 53 | 0.100 |
Why?
|
| Homeodomain Proteins | 5 | 2015 | 468 | 0.100 |
Why?
|
| Sequence Homology, Nucleic Acid | 5 | 1995 | 155 | 0.100 |
Why?
|
| Receptors, Very Late Antigen | 1 | 1991 | 1 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2017 | 1267 | 0.100 |
Why?
|
| Adipocytes | 1 | 2013 | 199 | 0.100 |
Why?
|
| Immunophenotyping | 2 | 2023 | 278 | 0.100 |
Why?
|
| Chimera | 1 | 1991 | 60 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2006 | 2478 | 0.100 |
Why?
|
| Interleukin-6 | 4 | 2021 | 688 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 1125 | 0.100 |
Why?
|
| Mice, Inbred C3H | 3 | 2022 | 250 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 4596 | 0.100 |
Why?
|
| Receptor Aggregation | 2 | 2005 | 8 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2021 | 372 | 0.100 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2011 | 20 | 0.100 |
Why?
|
| Chromatography, Affinity | 5 | 1997 | 85 | 0.100 |
Why?
|
| Peritoneum | 1 | 2011 | 36 | 0.100 |
Why?
|
| Macrophage Activation | 2 | 2008 | 168 | 0.100 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2011 | 25 | 0.100 |
Why?
|
| Models, Biological | 3 | 2010 | 1715 | 0.100 |
Why?
|
| Glycoproteins | 3 | 2007 | 319 | 0.100 |
Why?
|
| RANK Ligand | 1 | 2010 | 28 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 136 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 333 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2017 | 1664 | 0.100 |
Why?
|
| Germinal Center | 5 | 2011 | 47 | 0.090 |
Why?
|
| United States | 7 | 2022 | 12555 | 0.090 |
Why?
|
| Binding Sites, Antibody | 2 | 2007 | 38 | 0.090 |
Why?
|
| Ophthalmic Solutions | 1 | 2010 | 66 | 0.090 |
Why?
|
| Microglia | 3 | 2016 | 221 | 0.090 |
Why?
|
| Phosphotyrosine | 2 | 2008 | 37 | 0.090 |
Why?
|
| Viral Envelope Proteins | 2 | 2007 | 80 | 0.090 |
Why?
|
| Injections | 1 | 2011 | 167 | 0.090 |
Why?
|
| Air Pollution | 1 | 2013 | 209 | 0.090 |
Why?
|
| Endoglin | 1 | 2010 | 21 | 0.090 |
Why?
|
| Lymphocytes | 3 | 2021 | 347 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2019 | 396 | 0.090 |
Why?
|
| HLA-DR Antigens | 2 | 2008 | 224 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 2010 | 81 | 0.090 |
Why?
|
| Trachea | 1 | 2011 | 226 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6561 | 0.090 |
Why?
|
| Genes, rel | 1 | 2009 | 4 | 0.090 |
Why?
|
| Testosterone | 1 | 2013 | 351 | 0.090 |
Why?
|
| Fetal Growth Retardation | 2 | 2006 | 468 | 0.090 |
Why?
|
| Colorado | 3 | 2020 | 4196 | 0.090 |
Why?
|
| Interleukins | 2 | 2022 | 242 | 0.090 |
Why?
|
| Protein Interaction Mapping | 2 | 2008 | 104 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 1346 | 0.090 |
Why?
|
| Antigen Presentation | 2 | 2022 | 194 | 0.090 |
Why?
|
| Titrimetry | 1 | 2009 | 9 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2009 | 91 | 0.090 |
Why?
|
| Cryoglobulins | 3 | 2004 | 7 | 0.090 |
Why?
|
| Genetic Vectors | 3 | 2008 | 302 | 0.090 |
Why?
|
| Osteoarthritis | 1 | 2011 | 176 | 0.090 |
Why?
|
| Cytidine Deaminase | 1 | 2009 | 57 | 0.090 |
Why?
|
| Sodium Chloride | 2 | 2008 | 144 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2015 | 1636 | 0.090 |
Why?
|
| Pancreas | 2 | 2023 | 282 | 0.090 |
Why?
|
| Models, Animal | 2 | 2017 | 363 | 0.090 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2008 | 7 | 0.090 |
Why?
|
| Pulmonary Fibrosis | 1 | 2011 | 303 | 0.080 |
Why?
|
| Graft Rejection | 2 | 2011 | 555 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2015 | 671 | 0.080 |
Why?
|
| Immunological Synapses | 1 | 2008 | 18 | 0.080 |
Why?
|
| Ion Transport | 1 | 2008 | 60 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2021 | 1171 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 2008 | 30 | 0.080 |
Why?
|
| Albuminuria | 5 | 2015 | 195 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2009 | 291 | 0.080 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2008 | 69 | 0.080 |
Why?
|
| Chromosomes | 1 | 1989 | 87 | 0.080 |
Why?
|
| Dimerization | 2 | 2008 | 183 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2010 | 140 | 0.080 |
Why?
|
| Culture Media | 1 | 2008 | 163 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2008 | 69 | 0.080 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2018 | 15 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 167 | 0.080 |
Why?
|
| Interleukin-2 | 5 | 2016 | 416 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1794 | 0.080 |
Why?
|
| Diarrhea | 1 | 2009 | 181 | 0.080 |
Why?
|
| fas Receptor | 3 | 2014 | 98 | 0.080 |
Why?
|
| Freund's Adjuvant | 1 | 2008 | 17 | 0.080 |
Why?
|
| Zymosan | 2 | 2007 | 64 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 1798 | 0.080 |
Why?
|
| Liver Regeneration | 1 | 2008 | 34 | 0.080 |
Why?
|
| Ion Channels | 1 | 2008 | 126 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 310 | 0.080 |
Why?
|
| Siblings | 2 | 2010 | 235 | 0.080 |
Why?
|
| Allergens | 1 | 2011 | 424 | 0.080 |
Why?
|
| CHO Cells | 4 | 2012 | 143 | 0.080 |
Why?
|
| Brain Ischemia | 1 | 2011 | 310 | 0.080 |
Why?
|
| Receptors, Immunologic | 1 | 1989 | 209 | 0.080 |
Why?
|
| DNA, Complementary | 3 | 2006 | 268 | 0.080 |
Why?
|
| Glutathione | 2 | 1999 | 324 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2008 | 269 | 0.080 |
Why?
|
| Cricetinae | 4 | 2012 | 262 | 0.080 |
Why?
|
| Genes, Regulator | 5 | 1992 | 33 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 7 | 1996 | 332 | 0.080 |
Why?
|
| Calcium Channels | 1 | 2008 | 150 | 0.080 |
Why?
|
| Dependovirus | 1 | 2008 | 52 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 306 | 0.080 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2007 | 5 | 0.080 |
Why?
|
| In Situ Hybridization | 2 | 2006 | 311 | 0.080 |
Why?
|
| Elapid Venoms | 2 | 2005 | 16 | 0.080 |
Why?
|
| Receptors, HIV | 1 | 2007 | 23 | 0.080 |
Why?
|
| Interphase | 2 | 1998 | 30 | 0.080 |
Why?
|
| Antibodies, Blocking | 1 | 2007 | 32 | 0.080 |
Why?
|
| Aging | 2 | 2009 | 1670 | 0.080 |
Why?
|
| Protein Folding | 1 | 2009 | 250 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 1993 | 739 | 0.080 |
Why?
|
| Chemokine CXCL2 | 1 | 2007 | 44 | 0.080 |
Why?
|
| Contrast Media | 1 | 2010 | 373 | 0.080 |
Why?
|
| Phylogeny | 2 | 2021 | 816 | 0.080 |
Why?
|
| Blister | 1 | 2007 | 39 | 0.070 |
Why?
|
| Apolipoprotein E3 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Venae Cavae | 1 | 2006 | 10 | 0.070 |
Why?
|
| Immunocompetence | 1 | 2007 | 43 | 0.070 |
Why?
|
| Arthritis | 1 | 2008 | 112 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 3360 | 0.070 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 69 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2009 | 2851 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2010 | 1293 | 0.070 |
Why?
|
| Virion | 1 | 2007 | 78 | 0.070 |
Why?
|
| Multiprotein Complexes | 2 | 2005 | 149 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 5 | 1999 | 874 | 0.070 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2006 | 8 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 114 | 0.070 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2006 | 22 | 0.070 |
Why?
|
| Growth Cones | 1 | 2006 | 6 | 0.070 |
Why?
|
| Lupus Vulgaris | 1 | 2006 | 5 | 0.070 |
Why?
|
| International Cooperation | 2 | 2020 | 177 | 0.070 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2006 | 51 | 0.070 |
Why?
|
| DNA Primers | 5 | 2003 | 533 | 0.070 |
Why?
|
| Scattering, Radiation | 4 | 2008 | 93 | 0.070 |
Why?
|
| Random Allocation | 2 | 2006 | 344 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2020 | 143 | 0.070 |
Why?
|
| HIV | 1 | 2007 | 210 | 0.070 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 6 | 1994 | 103 | 0.070 |
Why?
|
| HLA-DRB1 Chains | 3 | 2014 | 97 | 0.070 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 147 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2010 | 1323 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 394 | 0.070 |
Why?
|
| Complement C9 | 2 | 2003 | 5 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2014 | 4708 | 0.070 |
Why?
|
| Smoking Prevention | 1 | 2006 | 150 | 0.070 |
Why?
|
| Basement Membrane | 1 | 2005 | 32 | 0.070 |
Why?
|
| Placental Insufficiency | 1 | 2006 | 104 | 0.070 |
Why?
|
| Pichia | 2 | 2003 | 20 | 0.070 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2021 | 213 | 0.060 |
Why?
|
| Gestational Age | 1 | 2008 | 765 | 0.060 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2005 | 18 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 305 | 0.060 |
Why?
|
| Mesenteric Arteries | 1 | 2004 | 16 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 536 | 0.060 |
Why?
|
| Bone Marrow | 2 | 1997 | 255 | 0.060 |
Why?
|
| Sequence Alignment | 2 | 2005 | 336 | 0.060 |
Why?
|
| Static Electricity | 1 | 2005 | 121 | 0.060 |
Why?
|
| Integrins | 2 | 1995 | 82 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 770 | 0.060 |
Why?
|
| Survival | 1 | 2004 | 39 | 0.060 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2003 | 6 | 0.060 |
Why?
|
| Aquaporins | 1 | 2003 | 8 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2014 | 226 | 0.060 |
Why?
|
| Embryo, Mammalian | 2 | 2006 | 220 | 0.060 |
Why?
|
| Collagen Type VII | 2 | 2018 | 13 | 0.060 |
Why?
|
| Proteins | 2 | 2003 | 938 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 667 | 0.060 |
Why?
|
| Immunoglobulin E | 1 | 2005 | 365 | 0.060 |
Why?
|
| Adolescent | 6 | 2014 | 18480 | 0.060 |
Why?
|
| Crosses, Genetic | 2 | 2000 | 138 | 0.060 |
Why?
|
| Restriction Mapping | 4 | 1992 | 76 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 158 | 0.060 |
Why?
|
| Fever | 1 | 2005 | 283 | 0.060 |
Why?
|
| Neoplasms | 1 | 2017 | 2179 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 139 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2003 | 59 | 0.060 |
Why?
|
| Counseling | 1 | 2006 | 353 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 702 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2006 | 345 | 0.060 |
Why?
|
| Phosphoproteins | 2 | 1995 | 308 | 0.060 |
Why?
|
| X-Rays | 3 | 2008 | 26 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2005 | 227 | 0.050 |
Why?
|
| Leukotriene B4 | 1 | 2002 | 51 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2009 | 273 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 2 | 2017 | 207 | 0.050 |
Why?
|
| Fetus | 2 | 2006 | 690 | 0.050 |
Why?
|
| Endocytosis | 2 | 2015 | 156 | 0.050 |
Why?
|
| Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 108 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 161 | 0.050 |
Why?
|
| HLA-D Antigens | 1 | 2022 | 36 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2002 | 67 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2022 | 87 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2001 | 76 | 0.050 |
Why?
|
| B7-2 Antigen | 2 | 1998 | 25 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 100 | 0.050 |
Why?
|
| Mesentery | 1 | 2001 | 56 | 0.050 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2001 | 6 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2012 | 124 | 0.050 |
Why?
|
| Zinc | 1 | 2004 | 262 | 0.050 |
Why?
|
| Kinetics | 5 | 2008 | 1624 | 0.050 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2021 | 41 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 101 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2001 | 270 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2006 | 922 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 158 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 70 | 0.050 |
Why?
|
| Antigens, Heterophile | 1 | 2000 | 4 | 0.050 |
Why?
|
| Antibodies, Heterophile | 1 | 2000 | 13 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2001 | 146 | 0.050 |
Why?
|
| Serum Amyloid P-Component | 1 | 2000 | 4 | 0.050 |
Why?
|
| Enteritis | 1 | 2001 | 78 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 148 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 3174 | 0.050 |
Why?
|
| Placenta | 2 | 2006 | 638 | 0.050 |
Why?
|
| Stem Cells | 1 | 2005 | 559 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 356 | 0.050 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 3 | 0.050 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 7 | 0.050 |
Why?
|
| B-Cell Activating Factor | 1 | 2020 | 18 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1687 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2020 | 22 | 0.050 |
Why?
|
| Vitrectomy | 1 | 2020 | 58 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2020 | 67 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2021 | 249 | 0.050 |
Why?
|
| Clone Cells | 1 | 2000 | 248 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 40 | 0.050 |
Why?
|
| Influenza A virus | 2 | 1998 | 90 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2000 | 95 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2000 | 83 | 0.050 |
Why?
|
| Interleukin-1alpha | 1 | 2020 | 56 | 0.050 |
Why?
|
| Nitroso Compounds | 1 | 1999 | 6 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2001 | 318 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 1999 | 59 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2011 | 220 | 0.040 |
Why?
|
| Immune Sera | 3 | 2007 | 82 | 0.040 |
Why?
|
| Seroconversion | 1 | 2019 | 48 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 1999 | 77 | 0.040 |
Why?
|
| Mutant Proteins | 2 | 2010 | 100 | 0.040 |
Why?
|
| Mutation | 3 | 2016 | 3457 | 0.040 |
Why?
|
| Interferon-gamma | 3 | 2012 | 736 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 1244 | 0.040 |
Why?
|
| Tetraspanin 28 | 1 | 1998 | 4 | 0.040 |
Why?
|
| Lymphocyte Cooperation | 1 | 1998 | 50 | 0.040 |
Why?
|
| Interferons | 1 | 2020 | 151 | 0.040 |
Why?
|
| Nanomedicine | 1 | 2019 | 28 | 0.040 |
Why?
|
| Endotoxins | 1 | 2020 | 234 | 0.040 |
Why?
|
| Demyelinating Diseases | 2 | 2013 | 79 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2005 | 508 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 632 | 0.040 |
Why?
|
| Complement C4a | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 1999 | 93 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2001 | 595 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 379 | 0.040 |
Why?
|
| Cell Division | 2 | 2004 | 776 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1989 | 64 | 0.040 |
Why?
|
| Child | 4 | 2021 | 19129 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2020 | 147 | 0.040 |
Why?
|
| Blood Donors | 1 | 1999 | 109 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 239 | 0.040 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1998 | 46 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 48 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 353 | 0.040 |
Why?
|
| Deoxyribonuclease I | 1 | 1998 | 36 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 148 | 0.040 |
Why?
|
| Biological Transport | 1 | 2019 | 382 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 1989 | 74 | 0.040 |
Why?
|
| Immunoglobulin Switch Region | 1 | 1997 | 1 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2020 | 389 | 0.040 |
Why?
|
| Complement C4b | 2 | 1989 | 10 | 0.040 |
Why?
|
| Blood-Brain Barrier | 2 | 2012 | 108 | 0.040 |
Why?
|
| Peritoneal Cavity | 1 | 1997 | 23 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 1999 | 179 | 0.040 |
Why?
|
| Plasmodium berghei | 1 | 1997 | 7 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 75 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2018 | 99 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 187 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 465 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 703 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1384 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2001 | 758 | 0.040 |
Why?
|
| Brachial Artery | 1 | 2018 | 181 | 0.040 |
Why?
|
| Phosphofructokinase-2 | 1 | 2016 | 14 | 0.040 |
Why?
|
| Spodoptera | 2 | 2006 | 37 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 534 | 0.040 |
Why?
|
| Locomotion | 1 | 2017 | 83 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.040 |
Why?
|
| Mice, Inbred AKR | 1 | 1996 | 34 | 0.040 |
Why?
|
| Schwann Cells | 1 | 1996 | 27 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2011 | 613 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 625 | 0.040 |
Why?
|
| Malaria | 1 | 1997 | 60 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2015 | 305 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 1997 | 156 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2016 | 57 | 0.040 |
Why?
|
| Bacteria | 1 | 2023 | 757 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1996 | 60 | 0.040 |
Why?
|
| Lymphocyte Subsets | 2 | 2009 | 76 | 0.040 |
Why?
|
| Mice, Inbred Strains | 3 | 2006 | 405 | 0.040 |
Why?
|
| Thymus Gland | 1 | 1997 | 300 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2008 | 300 | 0.030 |
Why?
|
| Biomedical Research | 2 | 2013 | 612 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 92 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 636 | 0.030 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1995 | 12 | 0.030 |
Why?
|
| HIV-1 | 1 | 2001 | 776 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 371 | 0.030 |
Why?
|
| Measles virus | 1 | 1995 | 11 | 0.030 |
Why?
|
| Glomerular Mesangium | 1 | 1995 | 19 | 0.030 |
Why?
|
| Autoradiography | 2 | 1995 | 72 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 1998 | 940 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1995 | 18 | 0.030 |
Why?
|
| E-Box Elements | 1 | 2015 | 5 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2015 | 14 | 0.030 |
Why?
|
| Tumor Virus Infections | 2 | 1997 | 41 | 0.030 |
Why?
|
| Transplantation Tolerance | 1 | 2015 | 31 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2022 | 12978 | 0.030 |
Why?
|
| Vasodilation | 1 | 2018 | 457 | 0.030 |
Why?
|
| Insulin | 2 | 2023 | 2162 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2015 | 74 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2015 | 93 | 0.030 |
Why?
|
| RNA | 2 | 1991 | 833 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2015 | 186 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 683 | 0.030 |
Why?
|
| Fibronectins | 2 | 1995 | 114 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 1996 | 228 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 1995 | 134 | 0.030 |
Why?
|
| Complement C5b | 1 | 2014 | 4 | 0.030 |
Why?
|
| Immune System | 2 | 2009 | 181 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2014 | 34 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2009 | 130 | 0.030 |
Why?
|
| Surface Properties | 1 | 2015 | 397 | 0.030 |
Why?
|
| Receptors, Fibronectin | 2 | 1995 | 6 | 0.030 |
Why?
|
| Antigens, Nuclear | 2 | 2010 | 18 | 0.030 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2014 | 20 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 578 | 0.030 |
Why?
|
| Vaccination | 2 | 2017 | 1222 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 355 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 1993 | 59 | 0.030 |
Why?
|
| ADAMTS13 Protein | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1994 | 146 | 0.030 |
Why?
|
| Chromatin | 2 | 2015 | 441 | 0.030 |
Why?
|
| Tyrosine | 1 | 1994 | 233 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2001 | 1570 | 0.030 |
Why?
|
| Microbiota | 1 | 2021 | 656 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 1997 | 181 | 0.030 |
Why?
|
| Otitis Media | 1 | 2016 | 146 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1419 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2013 | 59 | 0.030 |
Why?
|
| Hypoxia | 1 | 2020 | 963 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2013 | 26 | 0.030 |
Why?
|
| DNA Probes | 2 | 1992 | 60 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 2 | 2010 | 220 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2013 | 40 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2012 | 16 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 139 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 21 | 0.030 |
Why?
|
| Interleukin-9 | 1 | 2012 | 11 | 0.030 |
Why?
|
| HIV Infections | 1 | 2007 | 2459 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 27 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 1515 | 0.030 |
Why?
|
| Oxidants | 1 | 2013 | 122 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 681 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1527 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2016 | 467 | 0.030 |
Why?
|
| Models, Structural | 1 | 1992 | 38 | 0.030 |
Why?
|
| Arthrography | 1 | 2011 | 22 | 0.030 |
Why?
|
| Rituximab | 1 | 2013 | 155 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1995 | 359 | 0.030 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2011 | 25 | 0.030 |
Why?
|
| Lung Compliance | 1 | 2011 | 49 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 585 | 0.030 |
Why?
|
| Knee Joint | 1 | 2015 | 353 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1989 | 193 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2011 | 165 | 0.030 |
Why?
|
| Insulinoma | 1 | 1991 | 29 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 2 | 2006 | 17 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 280 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 305 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 1991 | 32 | 0.020 |
Why?
|
| Extracellular Fluid | 1 | 2011 | 32 | 0.020 |
Why?
|
| Vasculitis | 2 | 2003 | 75 | 0.020 |
Why?
|
| SOXD Transcription Factors | 1 | 2010 | 5 | 0.020 |
Why?
|
| Philippines | 1 | 2010 | 55 | 0.020 |
Why?
|
| Particulate Matter | 1 | 2013 | 244 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 160 | 0.020 |
Why?
|
| Microcirculation | 1 | 2011 | 155 | 0.020 |
Why?
|
| Exercise | 1 | 2021 | 1657 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 408 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2326 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 296 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2001 | 55 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 539 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 1990 | 63 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 940 | 0.020 |
Why?
|
| Neutrophil Infiltration | 2 | 2001 | 97 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2010 | 35 | 0.020 |
Why?
|
| Smoke | 1 | 2011 | 143 | 0.020 |
Why?
|
| Survival Rate | 2 | 2005 | 1720 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 181 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 98 | 0.020 |
Why?
|
| Extracellular Matrix | 2 | 2004 | 446 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 633 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 404 | 0.020 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 1989 | 8 | 0.020 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 2009 | 2 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 1079 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 1989 | 9 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 394 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1989 | 510 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2010 | 73 | 0.020 |
Why?
|
| Ascitic Fluid | 1 | 1989 | 15 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2010 | 156 | 0.020 |
Why?
|
| Myocardium | 1 | 2015 | 970 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1990 | 140 | 0.020 |
Why?
|
| Cosmids | 1 | 1989 | 5 | 0.020 |
Why?
|
| Serum | 1 | 2009 | 63 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2011 | 206 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1990 | 381 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 407 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 699 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 105 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 467 | 0.020 |
Why?
|
| Codon | 1 | 1989 | 89 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 1990 | 215 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1988 | 67 | 0.020 |
Why?
|
| Foot | 1 | 2009 | 106 | 0.020 |
Why?
|
| Buffers | 1 | 2008 | 56 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 181 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 412 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 1989 | 94 | 0.020 |
Why?
|
| Poly A | 1 | 1988 | 47 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2008 | 66 | 0.020 |
Why?
|
| Virulence | 1 | 2009 | 240 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2013 | 671 | 0.020 |
Why?
|
| Rheumatoid Nodule | 1 | 2008 | 6 | 0.020 |
Why?
|
| Gene Targeting | 2 | 2000 | 80 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 2007 | 52 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2008 | 138 | 0.020 |
Why?
|
| Exons | 1 | 1988 | 307 | 0.020 |
Why?
|
| Point Mutation | 1 | 2008 | 228 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 307 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2007 | 116 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 1945 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1987 | 53 | 0.020 |
Why?
|
| Veterans | 1 | 2018 | 1208 | 0.020 |
Why?
|
| Simplexvirus | 1 | 1987 | 86 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2006 | 7 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 749 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2007 | 48 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1541 | 0.020 |
Why?
|
| Neutrons | 1 | 2006 | 5 | 0.020 |
Why?
|
| Synchrotrons | 1 | 2006 | 9 | 0.020 |
Why?
|
| Rodentia | 1 | 2006 | 47 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 164 | 0.020 |
Why?
|
| Placenta Diseases | 1 | 2006 | 14 | 0.020 |
Why?
|
| Pliability | 1 | 2006 | 46 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2006 | 46 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2006 | 48 | 0.020 |
Why?
|
| Glycosylation | 1 | 2006 | 129 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 1203 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2010 | 9491 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2006 | 176 | 0.020 |
Why?
|
| Cycloheximide | 1 | 1985 | 57 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2009 | 378 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2006 | 127 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 580 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 709 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2003 | 455 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1985 | 48 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 200 | 0.020 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2004 | 3 | 0.020 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2004 | 5 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 270 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2005 | 93 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2005 | 73 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 774 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2007 | 198 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 1985 | 50 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 210 | 0.020 |
Why?
|
| Oxidants, Photochemical | 1 | 2003 | 8 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 1991 | 734 | 0.020 |
Why?
|
| Swine | 1 | 2006 | 730 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2003 | 53 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2003 | 11 | 0.010 |
Why?
|
| Procollagen | 1 | 2003 | 21 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2003 | 21 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 380 | 0.010 |
Why?
|
| Neutron Diffraction | 1 | 2003 | 3 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 2003 | 54 | 0.010 |
Why?
|
| U937 Cells | 1 | 2003 | 26 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2003 | 55 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 290 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 82 | 0.010 |
Why?
|
| Neutrophil Activation | 1 | 2003 | 100 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 413 | 0.010 |
Why?
|
| Dermatitis | 1 | 2003 | 16 | 0.010 |
Why?
|
| Aquaporin 4 | 1 | 2003 | 87 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 2003 | 86 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 210 | 0.010 |
Why?
|
| Hindlimb | 1 | 2003 | 137 | 0.010 |
Why?
|
| Ozone | 1 | 2003 | 109 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2006 | 486 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 1047 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 164 | 0.010 |
Why?
|
| Creatinine | 1 | 2004 | 491 | 0.010 |
Why?
|
| Pyelonephritis | 1 | 2001 | 8 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 369 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 2001 | 23 | 0.010 |
Why?
|
| Eicosanoids | 1 | 2001 | 57 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 516 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2001 | 165 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 150 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 225 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2001 | 146 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2001 | 198 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 462 | 0.010 |
Why?
|
| Escherichia coli Infections | 1 | 2001 | 105 | 0.010 |
Why?
|
| HeLa Cells | 2 | 1995 | 583 | 0.010 |
Why?
|
| S-Nitrosoglutathione | 1 | 1999 | 7 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 2000 | 111 | 0.010 |
Why?
|
| Deoxyribonucleotides | 1 | 1999 | 17 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1999 | 26 | 0.010 |
Why?
|
| Nitrites | 1 | 1999 | 81 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 136 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1999 | 35 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 83 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 154 | 0.010 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1998 | 20 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1998 | 63 | 0.010 |
Why?
|
| Copper | 1 | 1999 | 102 | 0.010 |
Why?
|
| IgG Deficiency | 1 | 1998 | 8 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 1998 | 31 | 0.010 |
Why?
|
| Genetic Linkage | 2 | 1990 | 321 | 0.010 |
Why?
|
| Asthma | 1 | 2011 | 2158 | 0.010 |
Why?
|
| Trophoblasts | 1 | 2000 | 169 | 0.010 |
Why?
|
| Antigens, Protozoan | 1 | 1997 | 19 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 1999 | 267 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 244 | 0.010 |
Why?
|
| Complement C8 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Endothelium | 1 | 1997 | 120 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1996 | 151 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 1996 | 59 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 8293 | 0.010 |
Why?
|
| Immunity | 1 | 1997 | 129 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1997 | 142 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1995 | 18 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 1995 | 7 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 1995 | 17 | 0.010 |
Why?
|
| Heymann Nephritis Antigenic Complex | 1 | 1995 | 2 | 0.010 |
Why?
|
| Laminin | 1 | 1995 | 68 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1996 | 399 | 0.010 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1994 | 11 | 0.010 |
Why?
|
| CD18 Antigens | 1 | 1994 | 35 | 0.010 |
Why?
|
| Paxillin | 1 | 1994 | 10 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1994 | 67 | 0.010 |
Why?
|
| Tunicamycin | 1 | 1994 | 11 | 0.010 |
Why?
|
| Methionine | 1 | 1995 | 145 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1995 | 135 | 0.010 |
Why?
|
| Asparagine | 1 | 1994 | 30 | 0.010 |
Why?
|
| Sepsis | 1 | 2000 | 531 | 0.010 |
Why?
|
| Oligosaccharides | 1 | 1994 | 54 | 0.010 |
Why?
|
| Cysteine | 1 | 1995 | 184 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1994 | 171 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1994 | 133 | 0.010 |
Why?
|
| Liposomes | 1 | 1994 | 151 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 1992 | 60 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 394 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1991 | 245 | 0.010 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 1989 | 58 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 1989 | 26 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1992 | 495 | 0.000 |
Why?
|
| Interleukin-1 | 1 | 1992 | 980 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1988 | 348 | 0.000 |
Why?
|
| Tosylphenylalanyl Chloromethyl Ketone | 1 | 1986 | 3 | 0.000 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1986 | 43 | 0.000 |
Why?
|
| Glycoside Hydrolases | 1 | 1986 | 30 | 0.000 |
Why?
|
| Heterozygote | 1 | 1987 | 262 | 0.000 |
Why?
|
| Granulocytes | 1 | 1986 | 79 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1985 | 38 | 0.000 |
Why?
|
| Mitogens | 1 | 1985 | 57 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1985 | 204 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1986 | 490 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1991 | 1939 | 0.000 |
Why?
|